Therapy

Despite FDA warnings and a 315% increased erythrocytosis risk with TRT, the asso

closed · Rounds: 4 · Score: 0.83 · 2026-04-14

Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of M

Score: 0.887 · neurodegeneration · 2026-04-16

## Mechanistic Overview Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial State

Beta-frequency entrainment therapy targeting PV interneuron-astrocyte coupling f

Score: 0.846 · Alzheimer's disease · 2026-04-05

## Mechanistic Overview Beta-frequency entrainment therapy targeting PV interneuron-astrocyte coupling for tau clearance

Kinetic Modeling Predicts Threshold-Dependent Efficacy—Early Intervention Requir

Score: 0.765 · protein folding · 2026-04-22

**Molecular Mechanism and Rationale** The therapeutic hypothesis centers on the kinetic constraints governing chaperone

Targeted APOE4-to-APOE3 Base Editing Therapy

Score: 0.758 · neurodegeneration · 2026-04-02

**Molecular Mechanism and Rationale** The apolipoprotein E4 (APOE4) variant represents the most significant genetic ris

Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enh

Score: 0.742 · neurodegeneration · 2026-04-02

## Mechanistic Overview Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enhancement starts

APOE4-Selective Lipid Nanoemulsion Therapy

Score: 0.742 · neurodegeneration · 2026-04-02

## Mechanistic Overview APOE4-Selective Lipid Nanoemulsion Therapy starts from the claim that modulating APOE within the

PARP1 Inhibition Therapy

Score: 0.738 · neurodegeneration · 2026-04-02

## Mechanistic Overview PARP1 Inhibition Therapy starts from the claim that modulating PARP1 within the disease context

Selective Neutral Sphingomyelinase-2 Inhibition Therapy

Score: 0.731 · neurodegeneration · 2026-04-12

**Molecular Mechanism and Rationale** The pathophysiological foundation of this therapeutic approach centers on the dys

APOE Isoform Conversion Therapy

Score: 0.718 · neurodegeneration · 2026-04-02

## Mechanistic Overview APOE Isoform Conversion Therapy starts from the claim that modulating APOE within the disease co

Circadian Glymphatic Rescue Therapy (Melatonin-focused)

Score: 0.712 · neurodegeneration · 2026-04-02

## Mechanistic Overview Circadian Glymphatic Rescue Therapy (Melatonin-focused) starts from the claim that modulating MT

Early Proteasome Restoration Therapy

Score: 0.712 · neurodegeneration · 2026-04-04

## Molecular Mechanism and Rationale The 26S proteasome represents the primary degradation machinery for misfolded and

Orexin-Microglia Modulation Therapy

Score: 0.707 · neurodegeneration · 2026-04-02

## Mechanistic Overview Orexin-Microglia Modulation Therapy starts from the claim that modulating HCRTR2 within the dise

TET2-Mediated Demethylation Rejuvenation Therapy

Score: 0.706 · neurodegeneration · 2026-04-02

## Mechanistic Overview TET2-Mediated Demethylation Rejuvenation Therapy starts from the claim that modulating TET2 with

Purinergic P2Y12 Inverse Agonist Therapy

Score: 0.703 · neurodegeneration · 2026-04-02

## Mechanistic Overview Purinergic P2Y12 Inverse Agonist Therapy starts from the claim that modulating P2RY12 within the